Trial · NCT07879638
A Study to Determine the Effect of Access to Multiple Tobacco Flavor Options on Smoking Abstinence Among Primary Cigarette Smokers Using an Electronic Nicotine Delivery System
NCT07879638, Not applicable, Recruiting, RAI Services Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Determine the Effect of Access to Multiple Tobacco Flavor Options on Smoking Abstinence Among Primary Cigarette Smokers Using an Electronic Nicotine Delivery System. Trials, record NCT07879638. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879638
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Determine the Effect of Access to Multiple Tobacco Flavor Options on Smoking Abstinence Among Primary Cigarette Smokers Using an Electronic Nicotine Delivery System
- NCT number
- NCT07879638
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 480 participants, estimated
- Lead sponsor
- RAI Services Company
- Conditions
- Smoking, Tobacco
- Interventions
- FT25614, FT25615, FT25616
- First posted
- 2026-10-19
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Impact of varying levels of access to tobacco flavor options | 13 weeks | To evaluate the impact of varying levels of access to Vuse ENDS tobacco flavor options on the rate of final 7-day abstinence from smoking CC among U.S. adult smokers at the end of a 13-week intervention period. The rate of final 7-day abstinence among participants with access to multiple tobacco flavor options in this study will be compared to the rate of final 7-day abstinence in the single tobacco flavor comparator arm in an RCT conducted earlier. |
| Secondary | Complete Switching | 13 weeks | Analyses of complete switching (defined as being abstinent from smoking CCs as well as being an adopted user of the Study IP) between participants in this study with access to multiple tobacco flavors and the single tobacco flavor comparator arm from a RCT conducted earlier, as well as between preferred flavor groups |
| Secondary | Abstinence Between Flavor Groups | 13 weeks | Additional analyses will evaluate abstinence between preferred flavor groups; time to first 7-day abstinence between this study and the single tobacco flavor comparator arm from the prior study, and between preferred flavor groups within this study; reductions in CPD from baseline to end of study; and ≥50% CPD reductions between this study and the single tobacco flavor comparator arm in an RCT conducted earlier. |
| Other | Topography | 13 Weeks | Puffing topography, quit attempts, descriptives of Study IP liking, intent to substitute CCs with Study IP, and intent to purchase will be summarized numerically. |
| Other | Demographics | 13 Weeks | Demographic characteristics of the study population will be tabulated and summarized numerically. |
| Other | AEs | 13 Weeks | The study will monitor any adverse events/experiences among participants using the Study IP. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879638
GET https://conductscience.org/api/trials/v1/NCT07879638/registered